Target Information
Target General Infomation | Top | ||||
---|---|---|---|---|---|
Target ID |
T90038
|
||||
Target Name |
HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway)
|
||||
Target Status |
Target in Phase 2 Trial
|
[1] | |||
Disease | [+] 1 Target-related Diseases | + | |||
1 | COVID-19 [ICD-11: 1D6Y] |
Drugs and Modes of Action | Top | ||||
---|---|---|---|---|---|
Drugs in Phase 2 Trial | [+] 1 Drugs in Phase 2 Trial | + | |||
1 | Atorvastatin | Drug Info | Phase 2 Trial | COVID-19 | [2] |
Mode of Action | [+] 1 Modes of Action | + | |||
Inhibitor | [+] 1 Inhibitor drugs | + | |||
1 | Atorvastatin | Drug Info | [1] |
References | Top | ||||
---|---|---|---|---|---|
1 | Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042. | ||||
2 | ClinicalTrials.gov (NCT04380402) Atorvastatin in COVID-19. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.